RESEARCH TRIANGLE PARK, N.C., Dec. 13, 2022 -- Pappas Capital, a global venture capital and commercial development firm, announced today the appointment of Richard Staub as Venture Partner. His appointment...
The company pursued development of a reversible inhibitor of monoamine oxidase (MAOI) for treatment resistant depression. In addition, the company assembled a pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma, and obesity.
CeNeRx BioPharma
Cary, NC
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.